1. Induced Disease Models Products Neuronal Signaling
  2. Nervous System Disease Models Amyloid-β
  3. β-Amyloid (1-42), human TFA

β-Amyloid (1-42), human TFA  (Synonyms: Amyloid β-peptide (1-42) (human) TFA)

Cat. No.: HY-P1363 Purity: 99.88%
Handling Instructions Technical Support

β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Top Publications Citing Use of Products

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2024 Dec 23;21(1):327.  [Abstract]

    Protein levels in BV2 cell treated with or without BCAAs/ BCKAs for 4 h in the presence of Aβ (1 μM) and the corresponding quantification results (n = 3).

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul 24:178:117199.  [Abstract]

    The effect of NMN on the survival rate of β-Amyloid (1-42) (Aβ, 1 μM; 24 h)-induced PC12 cells was determined by MTT assay.

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    Immunofluorescence showed lost ARC expression after 10 μM Aβ treatment. For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    qRT-PCR showed decreased mRNA levels of ARC after 10 μM Aβ treatment (n = 3). For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2022 Apr 25;14:890134.  [Abstract]

    Western blotting analysis showed declined protein levels of ARC after 10 μM Aβ treatment (n = 3). For Aβ treatment, human β-Amyloid (1-42) (HY-P1363) was dissolved, and the solution was incubated for 3 days at 37°C to form oligomeric Aβ, and then cells were treated with 10 μM for 48 h.

    β-Amyloid (1-42), human TFA purchased from MedChemExpress. Usage Cited in: Aging. 2021 Jun 9;13(11):15569-15579.  [Abstract]

    10 μM Aβ increased the mRNA expression of GRIA1 and GRIN2A, and decreased GRIN1 mRNA expression. n = 3. For the Aβ treatment, cells were incubated with 10 μM human β-Amyloid (1-42) for 48 h.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death[1][2][3][4][5][6][7].

    In Vitro

    β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs of your downstream experimental schemes).
    Monomerization (HFIP-treated):
    1. Solid Aβ peptide is dissolved in cold hexafluoro-2-propanol (HFIP). The peptide is incubated at room temperature for at least 1 h to establish monomerization and randomization of structure.
    2. Conduct vacuum drying to remove all of HFIP, and the resulting peptide is stored as a film at -20°C or -80°C.
    Oligomer preparation
    3. The resulting film is dissolved in anhydrous DMSO/0.1M NaOH/1% ammonia solution at 5 mM. Then, dilute it with sterile double-distilled water to a certain concentration (eg: 200 μM) and ensure complete dissolution.
    4. Next, the solution is age 24-48 h at 4-8°C. The sample is then centrifuged at 14000g for 10 min at 4-8°C; the soluble oligomers are in the supernatant. The supernatant is diluted 10-200-fold for experiments.
    Fiber preparation:
    3. The resulting film is dissolved in anhydrous DMSO at 5 mM and then dilutes into the appropriate concentration and buffer (10 mM HCl) with vortexing.
    4. Next, the solution is age 24-48 h at 37°C to obtain Aβ42 fibrils.
    Note:
    1) When performing step 1, if there is a small amount of insoluble matter, the HFIP treatment time can be extended (such as overnight incubation), vortexing, or short-term ultrasound can be used; if there is still a small amount of insoluble matter, it is recommended to remove it by centrifugation or filtration.
    2) When performing step 2, if vacuum drying conditions are not available, nitrogen blowing can be attempted. Freeze-drying or natural evaporation in a fume hood is not recommended.
    3) If using PBS for dilution, it may cause the precipitation of the polypeptide.
    4) The aggregation form is unstable in the solution, it is recommended to prepare and use it immediately. If storage is required, it is recommended to store the peptides in a film form at -20°C or -80°C.

    β-Amyloid (1-42), human TFA is prepared into oligomers, exhibiting neurotoxicity:
    β-amyloid (1–42) peptide (60-180 μM, 48 h) could form oligomers significantly faster than Aβ40 and Aβ43 and Aβ42 oligomers (1-1000 μg/mL, 48 h) showed the greatest level of neurotoxicity in both SH-SY5Y and PC12 cells[10].
    Aβ42 oligomers (20 μM, 0-48 h) induces both apoptosis and autophagy in SH-SY5Y cells but only autophagy in U87 cells[11].
    Aβ42 oligomers (0.5 μM, 1 h) induces intracellular Ca2+ influx, mitochondrial reactive oxygen species (ROS) production and increases cell death in mouse neuroblastoma N2a cells[12].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    β-Amyloid (1-42), human TFA can be used in animal modeling to construct Alzheimer's disease models.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    4628.06

    Formula

    C205H312F3N55O62S

    Appearance

    Solid

    Color

    White to off-white

    Sequence

    Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala

    Sequence Shortening

    DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    Sealed storage, away from moisture

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (7.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    0.1 M NaOH : ≥ 25 mg/mL (5.40 mM)

    H2O : 25 mg/mL (5.40 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.2161 mL 1.0804 mL 2.1607 mL
    5 mM 0.0432 mL 0.2161 mL 0.4321 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.88%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    0.1 M NaOH / H2O / DMSO 1 mM 0.2161 mL 1.0804 mL 2.1607 mL 5.4018 mL
    5 mM 0.0432 mL 0.2161 mL 0.4321 mL 1.0804 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    β-Amyloid (1-42), human TFA
    Cat. No.:
    HY-P1363
    Quantity:
    MCE Japan Authorized Agent: